Comments
Drug major Cipla on Wednesday reported a 20 per cent dip in consolidated net profit to ₹ 322.24 crore for the December 2018 quarter, mainly on account of higher tax expenses.
The company had posted a net profit of ₹403.45 crore for the corresponding period of the previous fiscal, Cipla said in a BSE filing.
Consolidated total revenue from operations of the company stood at ₹4,007.54 crore for the quarter, compared with Rs 3,913.82 crore for the same period year ago.
“Overall, challenges in this quarter were along expected lines and we remain optimistic as we enter FY20. Our plan to drive YoY growth from the coming quarters in on track,” said Cipla Managing Director and Global Chief Executive Officer Umang Vohra.
This quarter, the US business has delivered strongly, as a result of scale-up of new launches. The company is tracking well on its guidance on limited competition launches and abbreviated new drug application (ANDA) approvals, he added.
“Our key focus markets remain growth anchors, we have built further on our existing specialty pipeline, and we continue to explore innovative ways of going beyond the pill to meet unmet patient needs,” Vohra said.
The tax expenses for the quarter stood at ₹125.68 crore. It had a tax benefit of ₹ 64.23 crore in the year-ago period.
Shares of Cipla Ltd were trading at Rs 527.95 on the BSE, up 3.75 per cent over the previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.